Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 7/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.46 |
| ▸ | SCD | O00767 | 5/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655103 | 0.85 | CRBN (0.57) | DDB1CRBNIKZF3PTPRCPTPN1 | |
| SCHEMBL23979952 | 0.80 | DDB1 (0.51) | DDB1CRBNIKZF3PTPRCPTPN1 | |
| SCHEMBL18596192 | 0.73 | CRBN (0.74) | DDB1CRBNIKZF3 | |
| SCHEMBL19954297 | 0.73 | CRBN (0.74) | DDB1CRBNIKZF3 | |
| SCHEMBL27239098 | 0.72 | CRBN (0.60) | DDB1CRBNIKZF3PARP1 | |
| SCHEMBL3654342 | 0.71 | DDB1 (0.59) | DDB1CRBNIKZF3 | |
| SCHEMBL3653400 | 0.71 | CRBN (0.59) | DDB1CRBNIKZF3 | |
| SCHEMBL3653606 | 0.71 | CRBN (0.59) | DDB1CRBNIKZF3 | |
| SCHEMBL13881359 | 0.71 | CRBN (0.59) | DDB1CRBNIKZF3 | |
| SCHEMBL19586745 | 0.71 | CRBN (0.76) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9119854-B2 | Methods for treating cancer using combination therapy | CELGENE CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140328832-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | CELGENE CORPORATION (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328832-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | TP53, TOP2A, BRCA1 | DDB1 59/4885CRBN 475/4885IKZF3 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.